These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 22722508)

  • 21. In vitro and in vivo metabolism of a novel cannabinoid-1 receptor inverse agonist, taranabant, in rats and monkeys.
    Reddy VB; Doss GA; Karanam BV; Samuel K; Lanza TJ; Lin LS; Yu NX; Zhang AS; Raab CE; Stearns RA; Kumar S
    Xenobiotica; 2010 Sep; 40(9):650-62. PubMed ID: 20608842
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neurocognitive performance during acute THC intoxication in heavy and occasional cannabis users.
    Ramaekers JG; Kauert G; Theunissen EL; Toennes SW; Moeller MR
    J Psychopharmacol; 2009 May; 23(3):266-77. PubMed ID: 18719045
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Profiling the subjective, psychomotor, and physiological effects of a hydrocodone/acetaminophen product in recreational drug users.
    Zacny JP; Gutierrez S; Bolbolan SA
    Drug Alcohol Depend; 2005 Jun; 78(3):243-52. PubMed ID: 15893155
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A study investigating the acute dose-response effects of 13 mg and 17 mg Delta 9- tetrahydrocannabinol on cognitive-motor skills, subjective and autonomic measures in regular users of marijuana.
    Weinstein A; Brickner O; Lerman H; Greemland M; Bloch M; Lester H; Chisin R; Sarne Y; Mechoulam R; Bar-Hamburger R; Freedman N; Even-Sapir E
    J Psychopharmacol; 2008 Jun; 22(4):441-51. PubMed ID: 18635724
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Taranabant, a novel cannabinoid type 1 receptor inverse agonist.
    Fremming BA; Boyd ST
    Curr Opin Investig Drugs; 2008 Oct; 9(10):1116-29. PubMed ID: 18821475
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A one-year study to assess the safety and efficacy of the CB1R inverse agonist taranabant in overweight and obese patients with type 2 diabetes.
    Kipnes MS; Hollander P; Fujioka K; Gantz I; Seck T; Erondu N; Shentu Y; Lu K; Suryawanshi S; Chou M; Johnson-Levonas AO; Heymsfield SB; Shapiro D; Kaufman KD; Amatruda JM
    Diabetes Obes Metab; 2010 Jun; 12(6):517-31. PubMed ID: 20518807
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Assessment of pharmacokinetics and pharmacodynamic effects related to abuse potential of a unique oral osmotic-controlled extended-release methylphenidate formulation in humans.
    Parasrampuria DA; Schoedel KA; Schuller R; Gu J; Ciccone P; Silber SA; Sellers EM
    J Clin Pharmacol; 2007 Dec; 47(12):1476-88. PubMed ID: 17962423
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative abuse liability and pharmacological effects of meprobamate, triazolam, and butabarbital.
    Zawertailo LA; Busto UE; Kaplan HL; Greenblatt DJ; Sellers EM
    J Clin Psychopharmacol; 2003 Jun; 23(3):269-80. PubMed ID: 12826989
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A randomized, double-blind, placebo-controlled, crossover study to evaluate the human abuse liability of solriamfetol, a selective dopamine and norepinephrine reuptake inhibitor.
    Carter LP; Henningfield JE; Wang YG; Lu Y; Kelsh D; Vince B; Sellers E
    J Psychopharmacol; 2018 Dec; 32(12):1351-1361. PubMed ID: 30269642
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Metabolism and excretion of [14C]taranabant, a cannabinoid-1 inverse agonist, in humans.
    Karanam B; Addy C; Bateman T; Reddy VB; Li S; Dean D; Li H; Jones A; Schenk D; Zhang AS; Braun M; Freeman A; Flach S; Stoch A; Chodakewitz J; Wagner JA; Kumar S
    Xenobiotica; 2010 Oct; 40(10):691-700. PubMed ID: 20722472
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Profiling the subjective, psychomotor, and physiological effects of tramadol in recreational drug users.
    Zacny JP
    Drug Alcohol Depend; 2005 Nov; 80(2):273-8. PubMed ID: 16005162
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cannabis and tolerance: acute drug impairment as a function of cannabis use history.
    Ramaekers JG; van Wel JH; Spronk DB; Toennes SW; Kuypers KP; Theunissen EL; Verkes RJ
    Sci Rep; 2016 May; 6():26843. PubMed ID: 27225696
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of the abuse potential of extended release hydromorphone versus immediate release hydromorphone.
    Shram MJ; Sathyan G; Khanna S; Tudor IC; Nath R; Thipphawong J; Sellers EM
    J Clin Psychopharmacol; 2010 Feb; 30(1):25-33. PubMed ID: 20075644
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A randomized trial of lifestyle modification and taranabant for maintaining weight loss achieved with a low-calorie diet.
    Wadden TA; Fujioka K; Toubro S; Gantz I; Erondu NE; Chen M; Suryawanshi S; Carofano W; Johnson-Levonas AO; Shapiro DR; Kaufman KD; Heymsfield SB; Amatruda JM
    Obesity (Silver Spring); 2010 Dec; 18(12):2301-10. PubMed ID: 20379151
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of the abuse potential of pitolisant, a selective H3-receptor antagonist/inverse agonist, for the treatment of adult patients with narcolepsy with or without cataplexy.
    Setnik B; McDonnell M; Mills C; Scart-Grès C; Robert P; Dayno JM; Schwartz JC
    Sleep; 2020 Apr; 43(4):. PubMed ID: 31626696
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effect of high-dose dronabinol (oral THC) maintenance on cannabis self-administration.
    Schlienz NJ; Lee DC; Stitzer ML; Vandrey R
    Drug Alcohol Depend; 2018 Jun; 187():254-260. PubMed ID: 29689485
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Single doses of THC and cocaine decrease proficiency of impulse control in heavy cannabis users.
    van Wel JH; Kuypers KP; Theunissen EL; Toennes SW; Spronk DB; Verkes RJ; Ramaekers JG
    Br J Pharmacol; 2013 Dec; 170(7):1410-20. PubMed ID: 24106872
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cognitive and subjective dose-response effects of acute oral Delta 9-tetrahydrocannabinol (THC) in infrequent cannabis users.
    Curran HV; Brignell C; Fletcher S; Middleton P; Henry J
    Psychopharmacology (Berl); 2002 Oct; 164(1):61-70. PubMed ID: 12373420
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cognition and motor control as a function of Delta9-THC concentration in serum and oral fluid: limits of impairment.
    Ramaekers JG; Moeller MR; van Ruitenbeek P; Theunissen EL; Schneider E; Kauert G
    Drug Alcohol Depend; 2006 Nov; 85(2):114-22. PubMed ID: 16723194
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Subjective and behavioral effects of diphenhydramine, lorazepam and methocarbamol: evaluation of abuse liability.
    Preston KL; Wolf B; Guarino JJ; Griffiths RR
    J Pharmacol Exp Ther; 1992 Aug; 262(2):707-20. PubMed ID: 1501118
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.